Biological
Stapokibart clinical trials
Also written CM310.
- studies test it
- 36
- open now
- 16
- in phase 3
- 11
- first study started
- 2019
Keep track of what changes. Save the stapokibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- CM310
- 24
Combined with it in one product
Studies by the year they started
36 studies that test it; most in 2023 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 18
- Phase 3
- 11
- Phase 4
- 1
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 7
Keymed Biosciences Co.Ltd (24) · Chengdu Kangnuoxing Biopharma,Inc. (3) · Beijing Tongren Hospital (3) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Huazhong University of Science and Technology (1) · First Affiliated Hospital of Chongqing Medical University (1) · Beijing Friendship Hospital (1)
Often tested with
Tested in the same studies.
Immune Checkpoint Inhibitors (1) · Mometasone Furoate (1) · Finotonlimab (1)
Studies
Open first, then newest update. How each study uses stapokibart is read from its arms, and is right about nine times in ten.
Testing it · 36
- Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisRecruitingPhase 3Chengdu Kangnuoxing Biopharma,Inc.NCT07678931Written as Stapokibart
- A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory LymphomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07791615Written as Stapokibart, immune checkpoint inhibitor
- Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)Not yet recruitingPhase 2Chengdu Kangnuoxing Biopharma,Inc.NCT07617324Written as Stapokibart injection
- Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingNot applicableBeijing Tongren HospitalNCT07616609Written as Stapokibart
- Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCRecruitingPhase 1Beijing Tongren HospitalNCT07040072Written as Stapokibart and Finotonlimab
- Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia SyndromeNot yet recruitingNot applicableHuazhong University of Science and TechnologyNCT07240376Written as Stapokibart (CM310)
- Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous PemphigoidNot yet recruitingPhase 3Chengdu Kangnuoxing Biopharma,Inc.NCT07210554Written as Stapokibart injection
- Efficacy and Safety of Stapokibart for Primary Cutaneous AmyloidosisNot yet recruitingNot applicableFirst Affiliated Hospital of Chongqing Medical UniversityNCT07143864Written as Stapokibart
- A Study of Stapokibatrt in Children Subjects With Atopic DermatitisNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07106372Written as Stapokibatrt
- Study of Stapokibatrt in Children Subjects With Atopic DermatitisNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT06956196Written as Stapokibatrt
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal PolypsNot yet recruitingPhase 4Beijing Tongren HospitalNCT06801353Written as Stapokibart
- Study of Stapokibart Injection in Patients With Allergic RhinitisRecruitingPhase 2Keymed Biosciences Co.LtdNCT06525597Written as Stapokibart Injection
- A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNot yet recruitingPhase 2/3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06547333Written as CM310
- A Study of CM310 in Subjects With Moderate to Severe AsthmaRecruitingPhase 2/3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05761028Written as CM310
- Study of CM310 in Subjects With Seasonal Allergic RhinitisNot yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06171074Written as CM310
- Study Evaluating the Pharmacokinetics of CM310 in Healthy SubjectsNot yet recruitingPhase 1Keymed Biosciences Co.LtdNCT06171048Written as CM310
- A Study of CM310 in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Keymed Biosciences Co.LtdNCT06116565Written as CM310
- Study on the Treatment of Prurigo Nodularis With Stapokibart InjectionCompletedPhase 3Keymed Biosciences Co.LtdNCT06424470Written as Stapokibart
- Study of CM310 in Adolescent Subjects With Atopic DermatisActive, not recruitingPhase 3Keymed Biosciences Co.LtdNCT06495229Written as CM310
- Study of CM310 Injection in Adolescent Subjects With Atopic DermatisCompletedPhase 3Keymed Biosciences Co.LtdNCT06277765Written as CM310
Codes
What other systems call stapokibart · ClinicalTrials.gg INT017129
- UNII (FDA) L2REN9TU2DSTAPOKIBARTOne source FDA
- NCI Thesaurus C188799StapokibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L2REN9TU2D | STAPOKIBART | One source FDA |
| NCI Thesaurus | C188799 | Stapokibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.